| Abstract
Objectives: It has been proposed that zinc-a2-glycoprotein and S100A1 are possibly linked to the development of
lipogenesis and obesity. We aimed to measure serum levels of S100A1 and zinc-a2-glycoprotein in patients with metabolic
syndrome and investigate any associations of these two novel peptides with each other or components of metabolic
syndrome.
Methods: Forty-four patients with metabolic syndrome and the equivalent number of healthy controls participated in
this study. The participants’ body mass index, waist circumference, systolic and diastolic blood pressure were measured.
Serum levels of low- and high-density lipoprotein cholesterol, total cholesterol, triglyceride, fasting blood sugar, insulin,
zinc-a2-glycoprotein and S100A1 protein were determined.
Results: Higher levels of anthropometric and lipid indices, metabolic factors and also SBP and DBP were observed in the
metabolic syndrome group. Serum S100A1 levels were significantly lower in the metabolic syndrome group than the
control group (P¼0.008). There was a strong positive correlation between serum zinc-a2-glycoprotein and S100A1
levels (r¼0.80, P<0.0001). Serum levels of both S100A1 (P¼0.03) and zinc-a2-glycoprotein (P¼0.02) were potentially
higher in subjects with hypertension than those with normal blood pressure, though these were found as part of multiple
testing.
Conclusion: The results indicate that changes in the circulating level of S100A1 protein occur in metabolic syndrome
patients. The strong correlation between serum zinc-a2-glycoprotein and S100A1 might suggest that production or
release of these two proteins could be related mechanistically. |